trending Market Intelligence /marketintelligence/en/news-insights/trending/vUDkqqQblEHd_nX8IZSEcA2 content esgSubNav
In This List

IDT Australia sells portion of clinical trial biz

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


IDT Australia sells portion of clinical trial biz

IDT Australia Ltd. sold an initial 61% interest in its clinical trial business.

Japan's I'rom Group Co. Ltd. paid A$10 million for the stake, which will be managed by newly formed CMAX Clinical Research Pty. Ltd.; IDT Australia will retain the remaining 39% of the business.

IDT Australia will off-load the rest of its holdings to I'rom Group within the next 12 months for at least A$4 million.

"IDT is now free to move forward to deploy the initial proceeds to bolster its balance sheet and selectively grow our generic drug portfolio," IDT Australia Managing Director Paul MacLeman said.